Obesity study: Tirzepatide vs Semaglutide
Official title Mechanisms of Weight Loss: Tirzepatide vs Semaglutide
ClinicalTrials.gov ID: NCT07900074
What this study is testing
What is Tirzepatide?
An investigational once‑weekly injectable medicine being studied as a potential treatment for obesity. It is designed to activate both GIP and GLP‑1 receptors to help regulate appetite and metabolism.
Also referred to as Mounjaro.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study wants to see if tirzepatide changes how the body uses or stores energy more than semaglutide.
- Who it's for
- Adults who are obese and do not have known diabetes.
- What's involved
- Participants will receive either tirzepatide or semaglutide once a week for 12 weeks and will have visits at the start and after 12 weeks that include a 24‑hour energy‑use test, an MRI scan, body composition measurements, a 3‑day meal plan, and stool samples.
- Time commitment
- The study lasts 12 weeks and requires two visits, one at the beginning and one at the end, plus weekly medication doses.
- Phase 4: studies an already-approved treatment
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 60
You may be able to join if
- Age 18-60 years
- Body mass index (BMI) \>30 kg/m2
- Stable body weight (\<5kg change in the 3 months prior to screening)
You likely can't join if
- History of type 1 or type 2 diabetes or current diagnosis
- Glucose-lowering or weight loss drugs in the last 3 months or planned in the next 3 months
- Prior or planned bariatric surgery or planned low calorie meal program in the next 3 months
- Known clinically significant gastric emptying abnormality (for example, severe gastroparesis or gastric outlet obstruction) or chronic GI symptoms...
- Known liver disease other than non-alcoholic fatty liver disease, or ALT \>3x ULN
- Intake of standard alcoholic drinks more than 21/week for men, or 14/week for women
See the full eligibility criteria
- Age 18-60 years
- Body mass index (BMI) \>30 kg/m2
- Stable body weight (\<5kg change in the 3 months prior to screening)
- History of type 1 or type 2 diabetes or current diagnosis
- Glucose-lowering or weight loss drugs in the last 3 months or planned in the next 3 months
- Prior or planned bariatric surgery or planned low calorie meal program in the next 3 months
- Known clinically significant gastric emptying abnormality (for example, severe gastroparesis or gastric outlet obstruction) or chronic GI symptoms (nausea, vomiting, diarrhea, constipation, bloating or unexplained...
- Known liver disease other than non-alcoholic fatty liver disease, or ALT \>3x ULN
- Intake of standard alcoholic drinks more than 21/week for men, or 14/week for women
- Estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m2
- History of pancreatitis
- Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia 2
- Currently pregnant/breastfeeding, previous pregnancy within the last 6 months, or unwillingness to use contraception for 3 months
- Other medications, allergies or comorbidities that, in the opinion of the investigator could interfere with study medication or study measures (e.g., catecholamine medications) or current medication use that has been...
- Claustrophobia precluding a 24 hour stay in a whole room calorimeter or MRI scan
- Inability to undergo MRI (weight \>250 kg, incompatible implanted device, e.g., pacemaker)
- Use of cannabis or its related products (d-9-THC, CBD, d-8-THC, and cannabinol) in the past three months
- Use of nicotine/tobacco that has been unstable in the past 8 weeks or expected to change within the next 3 months (exclusion from MRI visit ONLY)
- Known monogenic, syndromic hypothalamic causes of obesity
- Not able to communicate in English
- History of cardiac conditions that precludes exercise
- Participation in any intervention clinical study within 90 days before screening
- History of eating disorder within the last year
The study team makes the final eligibility decision.
Where it is enrolling
- Hamilton, Ontario, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 60 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Hamilton, Ontario, Canada. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.